
According to Validea's guru fundamental report, AbbVie (ABBV) receives a rating of 81% based on the Multi-Factor Investor model, which is based on the published strategy of Pim van Vliet. The model favors low volatility stocks with strong momentum and high net payout yields. While ABBV passes the market cap and standard deviation criteria, it is neutral on momentum and net payout yield, ultimately failing the final rank within this strategy.
AbbVie (ABBV) presents a nuanced profile under Validea's Multi-Factor Investor model, which is based on Pim van Vliet's strategy. The stock achieves an 81% rating, a score that typically signals some interest from the strategy due to its pursuit of low volatility, strong momentum, and high net payout yields. ABBV, a large-cap growth stock in the Biotechnology & Drugs sector, aligns with the model's low-volatility criteria by passing tests for market capitalization and standard deviation. However, it receives neutral assessments for twelve-minus-one momentum and net payout yield, which are also critical components of van Vliet's approach. Critically, despite the 81% initial score indicating some alignment, the detailed breakdown reveals a "FAIL" on the final rank for ABBV within this specific strategy, suggesting that while certain characteristics are attractive, the overall profile does not meet the stringent requirements for a full endorsement by this particular model.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
0.00
Ticker Sentiment